David S. Wichmann - Jul 1, 2021 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role: Director
Signature: /s/ Mai-Khoi Nguyen-Thanh, Attorney-in-Fact
Stock symbol: BSX
Transactions as of: Jul 1, 2021
Transactions value $: $0
Form type: 4
Date filed: 7/6/2021, 04:12 PM
Previous filing: Jun 28, 2021
Next filing: Nov 16, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BSX	Deferred Stock Units	Award	$0	+4.09K		$0.00	4.09K	Jul 1, 2021	Common Stock	4.09K		Direct	F1, F2, F3
transaction	BSX	Deferred Stock Units	Award	$0	+2.3K	+56.1%	$0.00	6.39K	Jul 1, 2021	Common Stock	2.3K		Direct	F1, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2	Reflects a value of approximately $177,500 (representing the prorated amount of the non-employee director compensation program's annual equity grant having a value of $205,000) divided by the closing price of common stock on the date of grant.
F3	Grant of deferred stock units to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2022 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.
F4	Reflects a value of approximately $99,600 (representing the prorated amount of the non-employee director compensation program's cash retainer having a value of $115,000) divided by the closing price of the common stock on the date of grant.
F5	Grant of deferred stock units in lieu of yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2022 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.